Drug
Zanzalintinib
Zanzalintinib: highest development phase Phase 2/3, developed by Exelixis. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Exelixis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Zanzalintinib NCT06943755 | Phase 2/3 | Pancreatic Neuroendocrine Tumor (pNET) |
| Zanzalintinib NCT07185945 | Phase 2 | Advanced Urothelial Carcinoma |
| Zanzalintinib NCT07193550 | Phase 2 | Bone Sarcomas |
| Zanzalintinib NCT07428616 | Phase 2 | Meningioma |
Latest
No recent events.
Follow Zanzalintinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.